These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32777481)

  • 21. The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition.
    Momtazi-Borojeni AA; Banach M; Ruscica M; Sahebkar A
    Expert Rev Clin Pharmacol; 2022 Oct; 15(10):1199-1208. PubMed ID: 36193738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients.
    Paredes-Turrubiarte G; González-Chávez A; Pérez-Tamayo R; Salazar-Vázquez BY; Hernández VS; Garibay-Nieto N; Fragoso JM; Escobedo G
    Clin Exp Med; 2016 May; 16(2):193-202. PubMed ID: 25894568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SFRP5 hepatic expression is associated with non-alcoholic liver disease in morbidly obese women.
    Gutiérrez-Vidal R; Vega-Badillo J; Reyes-Fermín LM; Hernández-Pérez HA; Sánchez-Muñoz F; López-Álvarez GS; Larrieta-Carrasco E; Fernández-Silva I; Méndez-Sánchez N; Tovar AR; Villamil-Ramírez H; Mejía-Domínguez AM; Villarreal-Molina T; Hernández-Pando R; Campos-Pérez F; Aguilar-Salinas CA; Canizales-Quinteros S
    Ann Hepatol; 2015; 14(5):666-74. PubMed ID: 26256895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute caloric restriction counteracts hepatic bile acid and cholesterol deficiency in morbid obesity.
    Straniero S; Rosqvist F; Edholm D; Ahlström H; Kullberg J; Sundbom M; Risérus U; Rudling M
    J Intern Med; 2017 May; 281(5):507-517. PubMed ID: 28261926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adipokine Levels Versus Hepatic Histopathology in Bariatric Surgery Patients.
    D'Incao RB; Tovo CV; Mattevi VS; Borges DO; Ulbrich JM; Coral GP; Ramos MJ; Meinhardt NG
    Obes Surg; 2017 Aug; 27(8):2151-2158. PubMed ID: 28281237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome.
    Wang M; Zhao D; Xu L; Guo W; Nie L; Lei Y; Long Y; Liu M; Wang Y; Zhang X; Zhang L; Li H; Zhang J; Yuan D; Yue L
    Metabolism; 2019 May; 94():47-58. PubMed ID: 30768966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery.
    Kukla M; Ciupińska-Kajor M; Kajor M; Wyleżoł M; Żwirska-Korczala K; Hartleb M; Berdowska A; Mazur W
    Pol J Pathol; 2010; 61(3):147-53. PubMed ID: 21225497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
    Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
    Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.
    Bedossa P; Poitou C; Veyrie N; Bouillot JL; Basdevant A; Paradis V; Tordjman J; Clement K
    Hepatology; 2012 Nov; 56(5):1751-9. PubMed ID: 22707395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis.
    Sabaté JM; Jouët P; Harnois F; Mechler C; Msika S; Grossin M; Coffin B
    Obes Surg; 2008 Apr; 18(4):371-7. PubMed ID: 18286348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters.
    Dong B; Singh AB; Shende VR; Liu J
    Int J Mol Med; 2017 Mar; 39(3):749-756. PubMed ID: 28204827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
    Guo S; Xia XD; Gu HM; Zhang DW
    Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sauchinone controls hepatic cholesterol homeostasis by the negative regulation of PCSK9 transcriptional network.
    Chae HS; You BH; Kim DY; Lee H; Ko HW; Ko HJ; Choi YH; Choi SS; Chin YW
    Sci Rep; 2018 Apr; 8(1):6737. PubMed ID: 29712938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Up-regulation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations.
    Sucajtys-Szulc E; Szolkiewicz M; Swierczynski J; Rutkowski B
    Atherosclerosis; 2016 May; 248():17-26. PubMed ID: 26978583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway.
    Zhu W; Ding C; Huang P; Ran J; Lian P; Tang Y; Dai W; Huang X
    Sci Rep; 2022 Apr; 12(1):5639. PubMed ID: 35379885
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Lebeau PF; Byun JH; Platko K; Al-Hashimi AA; Lhoták Š; MacDonald ME; Mejia-Benitez A; Prat A; Igdoura SA; Trigatti B; Maclean KN; Seidah NG; Austin RC
    JHEP Rep; 2019 Dec; 1(6):418-429. PubMed ID: 32039393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic expression of Yin Yang 1 (YY1) is associated with the non-alcoholic fatty liver disease (NAFLD) progression in patients undergoing bariatric surgery.
    Yuan X; Chen J; Cheng Q; Zhao Y; Zhang P; Shao X; Bi Y; Shi X; Ding Y; Sun X; Xue B
    BMC Gastroenterol; 2018 Oct; 18(1):147. PubMed ID: 30285651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
    Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI
    Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics.
    Gauthier MS; Awan Z; Bouchard A; Champagne J; Tessier S; Faubert D; Chabot K; Garneau PY; Rabasa-Lhoret R; Seidah NG; Ridker PM; Genest J; Coulombe B
    J Clin Lipidol; 2018; 12(4):1027-1038. PubMed ID: 29699916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.